A REVIEW ON GLP-1 RECEPTOR AGONISTS IN OBESITY AND TYPE 2 DIABETES MANAGEMENT

GLP-1 receptor agonists have proven to be a major therapeutic class in the treatment of obesity and T2DM due to their multi-metabolic mechanism of action. The pharmacological agents function in the same way as the endogenously produced GLP-1 by improving glucose-dependent insulin secretion, inhibition of glucagon secretion, slowing down of gastric emptying, and increasing satiety. As such, the agents result in better glycemic regulation as well as sustained weight loss. In addition to the multi-metabolic effects, GLP-1 receptor agonists have also been found to offer cardiovascular and kidney protection, and hence, are useful in individuals with multiple cardiometabolic risks. The agents have found application in areas other than the treatment of diabetes as well. In addition to being used in diabetes, the drugs are also used in chronic weight management and other obesity-related diseases. Current research is trying to investigate the utility of the drugs in metabolic dysfunction-associated steatotic liver disease, neurodegeneration, and precision medicine among other areas.

• Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne), 2023 Apr 21; 14: 1161521
• Sena CM, Bento CF, Pereira P, Seiça R. Diabetes mellitus: new challenges and innovative therapies. EPMA J., 2010 Mar; 1(1): 138-63.
• Alharbi AG. GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. Saudi Pharm J., 2025 Sep 24; 33(5): 34.
• Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne), 2021 Aug 23; 12: 721135.
• Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab., 2019 Dec; 30: 72-130.
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev., 2007 Oct; 87(4): 1409-39.
• Graaf Cd, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, Brown AJ, Zhou C, Deng J, Wang MW. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev., 2016 Oct; 68(4):        954-1013.
• Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther., 2024 Sep 18; 9(1): 234.
• Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne), 2024 Jul 24; 15: 1431292.
• Gonzalez-Rellan MJ, Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med., 2025 Jul 15; 6(7): 102214.
• Gonzalez-Rellan MJ, Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med., 2025 Jul 15; 6(7): 102214.
• Al-Noshokaty TM, Abdelhamid R, Abdelmaksoud NM, Khaled A, Hossam M, Ahmed R, Saber T, Khaled S, Elshaer SS, Abulsoud AI. Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential. Toxicol Rep., 2025 Jan 16; 14: 101895.
• Jin X, Qiu T, Li L, Yu R, Chen X, Li C, Proud CG, Jiang T. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B., 2023 Jun; 13(6): 2403-2424.
• Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci., 2020 Aug 30; 21(17): 6275.
• Fadel LP, Thao G, Chitre T, Rojas ED, Nguyen Fricko M, Domingo V, Budginas B, Guerrero LC, Ghatas M, Arani NT, Tabatabai N, Pemminati S. A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks. Cureus., 2025 Feb 5; 17(2): e78575.
• Kalra S, Bhattacharya S, Kapoor N. Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). Diabetes Ther., 2021 Aug; 12(8): 2133-2147.
• Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne), 2024 Jul 24; 15: 1431292. 
• Liu Z, Yu S, Jin X, Sheng L, YanMu MR, Gao J, Lu J, Lei T. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. Drug Des Devel Ther., 2025 Nov 22; 19: 10383-10409.
• Reiss AB, Gulkarov S, Lau R, Klek SP, Srivastava A, Renna HA, De Leon J. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules, 2025 Mar 13; 15(3): 408.
• Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas), 2019 May 31; 55(6): 233.
• Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr, 2017 Aug; 30(3): 202-210.
• Wang JY, Wang QW, Yang XY, Yang W, Li DR, Jin JY, Zhang HC, Zhang XF. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol (Lausanne), 2023 Feb 1; 14: 1085799.
• Gul U, Aung T, Martin M, Farrukh DN, Shah PC, Lovely ZS, Marroquín León E, Alansaari M, Maini S, Fariduddin MM, Ullah A, Nazir Z. A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure. Cureus., 2024 Dec 28; 16(12): e76519.
• Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther., 2021 Jun; 38(6): 2821-2839.
• Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci., 2023 Jun 21; 24(13): 10449.
• Ferhatbegović L, Mršić D, Macić-Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc, 2023 Dec 8; 4: 1293926.
• Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. Int J Mol Sci., 2022 Aug 24; 23(17): 9583.
• Sørensen KK, Gerds TA, Køber L, Loldrup Fosbøl E, Poulsen HE, Møller AL, Andersen MP, Pedersen-Bjergaard U, Torp-Pedersen C, Zareini B. Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study. J Diabetes, 2024 Oct; 16(10): e70000.
• Almohareb SN, Alfayez OM, Aljuaid SS, Alshahrani WA, Bakhsh G, Alshammari MK, Al Yami MS, Alshaya OA, Alomran AS, Korayem GB, Almohammed OA. Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes. J Clin Med., 2024 Oct 30; 13(21): 6532.
• Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest, 2026 Feb 16; 136(4): e194740.
• Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsbøll T. Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. Front Endocrinol (Lausanne), 2018 Nov 6; 9: 649.